Shionogi Announces $2.5 Billion Acquisition of ALS Drug Radicava from Tanabe Pharma

Shionogi will acquire a newly established company from Tanabe Pharma holding global rights to Radicava ORS (edaravone oral suspension) and IV Radicava, FDA-approved treatments for ALS, for $2.5 billion.

The deal was announced on December 22, 2025, making the new company a wholly owned subsidiary of Shionogi Inc.12

This acquisition strengthens Shionogi's rare disease portfolio and provides commercial infrastructure for future launches in areas like Fragile X syndrome, Jordan’s syndrome, and Pompe disease.12

Radicava targets oxidative stress and glutamate excitotoxicity in ALS, a neurodegenerative disease with limited treatment options.1

Shionogi may pay additional royalties on future sales under certain conditions.1

Sources:

1. https://globalgenes.org/raredaily/shionogi-expands-rare-disease-with-acquisition-of-als-therapy-in-2-5b-deal/

2. https://www.shionogi.com/us/en/news/2025/12/shionogi-expands-rare-disease-presence-with-planned-acquisition-of-global-rights-to-tanabe-pharma-corporations-radicava-ors-edaravone-and-iv-radicava.html